MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Leukemia, Hematologic, Blood
IN8bio (NASDAQ: INAB)*, formerly, Incysus Theapeutics
Organization & Developments: IN8bio
Parents
IN8bio (NASDAQ: INAB)*, formerly, Incysus Theapeutics
Children
2020: Bringing their genetically modified gamma delta T cells to Nasdaq, IN8bio files for $86M IPO
2020: Incysus Therapeutics Announces Name Change to IN8bio, Inc.
By using allogeneic and genetically modified gamma-delta (γδ) T cells, IN8bio’s technology addresses certain challenges that immunotherapies face targeting cold, low mutation cancers
IN8bio is focused on delivering novel immunotherapies for the treatment of cancer.
Jumps
Finance & Acquisitions: IN8bio
Key People: IN8bio